KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Accumulated Expenses (2016 - 2025)

Thermo Fisher Scientific's Accumulated Expenses history spans 17 years, with the latest figure at $2.0 billion for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses changed 0.35% year-over-year to $2.0 billion, compared with a TTM value of $2.0 billion through Dec 2025, changed 0.35%, and an annual FY2025 reading of $2.0 billion, changed 0.35% over the prior year.
  • Accumulated Expenses for Q4 2025 was $2.0 billion at Thermo Fisher Scientific, up from $1.9 billion in the prior quarter.
  • The five-year high for Accumulated Expenses was $2.4 billion in Q4 2021, with the low at $1.3 billion in Q2 2023.
  • Average Accumulated Expenses over 5 years is $1.7 billion, with a median of $1.6 billion recorded in 2022.
  • Year-over-year, Accumulated Expenses soared 74.04% in 2021 and then fell 23.93% in 2023.
  • Tracing TMO's Accumulated Expenses over 5 years: stood at $2.4 billion in 2021, then decreased by 13.68% to $2.1 billion in 2022, then fell by 23.82% to $1.6 billion in 2023, then grew by 24.56% to $2.0 billion in 2024, then increased by 0.35% to $2.0 billion in 2025.
  • Per Business Quant, the three most recent readings for TMO's Accumulated Expenses are $2.0 billion (Q4 2025), $1.9 billion (Q3 2025), and $1.5 billion (Q2 2025).